Aug 6 Bayer AG's experimental drug to
treat two types of pulmonary hypertension should be approved, an
advisory panel to the U.S. Food and Drug Administration said on
The panel voted 11-0 that the FDA should approve the drug,
riociguat, which in clinical trials extended the distance
patients could walk during a six-minute test.
The FDA is not obliged to follow the recommendation of its
advisory panel, but typically does so. If approved, the drug
would be sold under the brand name Adempas.
(Reporting by Toni Clarke in Washington; Editing by John
Wallace and Gerald E. McCormick)